Categories AlphaGraphs, Earnings, Health Care

LLY Earnings: Key quarterly highlights from Eli Lilly’s Q2 2023 financial results

Eli Lilly and Company (NYSE: LLY) reported second quarter 2023 earnings results today.

Revenue increased 28% to $8.3 billion compared to the same period a year ago, fueled by volume-driven growth from Mounjaro, Verzenio, Jardiance and Taltz, as well as the sale of rights for Baqsimi.

Reported net income grew 85% to $1.76 billion, or $1.95 per share, compared to last year. Adjusted EPS rose 69% to $2.11.

Both revenue and earnings beat expectations, sending the stock up by 7% in premarket hours on Tuesday.  

The company raised its guidance for the full year of 2023. Revenue is now expected to be $33.4-33.9 billion. Reported EPS is expected to be $9.20-9.40 while adjusted EPS is projected to be $9.70-9.90.

Prior performance

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top